Podcasts about Invasive

Stephen Ryu, a neurosurgeon and key figure in the Stanford Neuroprosthetics Lab joins Tjaša Zajc on Faces of Digital Health to demystify brain–computer interfaces (BCIs): how they work, why invasive systems outperform non-invasive ones, realistic use cases (motor control and speech), timelines and durability, safety and MRI trade-offs, cybersecurity, business models, and what Paradromics is building as a high-bandwidth BCI platform. Throughout, Stephen separates science fact from sci-fi, stressing near-term potential to restore communication and movement for people living with paralysis, while noting earlier-stage areas like mental health and pain. What we cover: - Invasive vs. non-invasive BCIs, and why electrode proximity to neurons matters for performance - Decoding motor intent and speech: training, language considerations, and LLM-enabled synthesis - Safety, surgery, and durability (why 10-year implant lifespans are a meaningful target) - MRI/CT compatibility trade-offs (and parallels to pacemakers/DBS) - Cybersecurity realities (what BCIs can not do today) - Business models, regulation, and reimbursement paths for medical-grade BCIs - Paradromics' differentiation: a high-bandwidth platform designed to scale across use cases - Future indications: pain, sensory restoration; earlier stage: mental health biomarkers - The human impact: restoring connection for people who can't move or speak Chapters: 01:37 How BCIs work; signals, decoding, invasive vs. non-invasive 07:13 Surgery basics, risks, and why proximity boosts performance 09:36 Decoding speech & language considerations 13:31 What's most advanced today: motor + speech 14:58 Mental health: biomarkers and why it's early 17:48 Longevity, MRI/CT limits, realistic replacement intervals 21:16 Patient perception: fear, performance, and value vs. alternatives 25:04 Paradromics' platform & high-bandwidth approach 29:22 Platform use cases by brain area (motor, auditory, etc.) 31:18 Cybersecurity: risks today vs. sci-fi 32:35 Business models, regulation, and access 36:42 Trials landscape; Paradromics' timeline 37:53 Biggest concerns: hype vs. reality 39:50 Three things everyone should know about BCIs 42:10 Potential in pain management 44:41 Role of AI/ML in decoding and assistive apps 46:36 Final thoughts www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/

Get ready to strike a pose and say “cheese” if you're heading to the U.S., because any visits to our southern neighbour will soon come with a photo op. Influencers, beware: Lululemon has opened a new front in its war on dupes.

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who's on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe conversation covers the efficacy and safety of checkpoint inhibitors like pembrolizumab, the importance of a multidisciplinary approach, and the challenges of balancing systemic and localized treatments. They also touch upon the potential future role of biomarkers in reducing invasive procedures and improving patient outcomes.---TIMESTAMPS00:00 - Introduction02:04 - The Role of Medical Oncologists in Bladder Cancer12:58 - Combination Therapies and Patient Outcomes21:18 - The CREST Study26:59 - Managing Adverse Events34:44 - Collaboration Between Urologists and Oncologists41:06 - Conclusion and Final Thoughts---RESOURCESCREST Trialhttps://www.nature.com/articles/s41591-025-03738-zCISTO Studyhttps://pubmed.ncbi.nlm.nih.gov/37980511/

More with Selah and Kori. An Honor Flight comes with a myriad of expectations. For Selah and Kori, how did their expectations match up with how the trip actually unfolded. And walking around every memorial, how did they do their jobs - with cameras that had huge lenses - without ever appearing invasive while veterans were experiencing a range of emotions based upon their memories. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

More with Selah and Kori. An Honor Flight comes with a myriad of expectations. For Selah and Kori, how did their expectations match up with how the trip actually unfolded. And walking around every memorial, how did they do their jobs - with cameras that had huge lenses - without ever appearing invasive while veterans were experiencing a range of emotions based upon their memories. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Die Neophyten wachsen uns immer mehr über den Kopf: fast wortwörtlich. Der Kanton Aargau ändert nun seine Strategie im Kampf gegen invasive Pflanzen. Zu den gefährlichsten gehört der Götterbaum: er wächste Jahr für Jahr um bis zu drei Meter. Die weiteren Themen dieser Sendung: · Der heutige Sturm hat in Grenchen schon eine Windböe mvon mehr als 100 Stundenkilometer gebracht - vereinzelt blockieren umgestürtzte Bäume kleinere Strassen. · Die Notschlafstelle in Olten sucht weitere Geldgeber. Die Solothurner Kantonsregierung sieht sich nicht in der Pflicht.

The Idaho Department of Agriculture treated the invasive species Quagga muscles in the fall of 2023 and 2024. Now they're back once again.

This episode explores the world of invasive edible plants and fungi, focusing on species like garlic mustard, kudzu, Japanese knotweed, and burdock. The hosts discuss their origins, ecological impacts, and how to responsibly forage and prepare these plants for sustainable meals. The conversation emphasizes the importance of proper identification and safety when foraging, while also sharing cooking tips and recipes. In this conversation, Justin Townsend and Adam Berkelmans delve into the world of foraging and cooking with invasive species. They explore the culinary potential of burdock, dandelions, Himalayan blackberries, and golden oyster mushrooms, discussing their flavors, nutritional benefits, and recipes. The discussion emphasizes the importance of culinary conservation and how foraging can contribute to ecosystem health. - ⁠⁠⁠⁠Leave a Review of the Podcast⁠⁠⁠⁠ - ⁠⁠⁠⁠Buy our Wild Fish and Game Spices⁠⁠⁠⁠ ⁠⁠⁠⁠The Art of Venison Sausage Making⁠⁠⁠⁠ Recipes: Wild Greens Mac and Cheese Stuffed Kudzu Leaves Barbecue Dolmas Stuffed with Bacon Beef and Cheese Japanese Knotweed Cake with Streusel Topping Summer Wild Vegetable TempuraHow to Make Dandelion Jelly Dandelion and Zucchini FrittersStewed Dandelion Greens with Chickpeas and ‘NdujaVenison Steak with Blackberry Sauce and Corn Salad Cacio e Pepe with Wild Pork Sausage and Oyster Mushrooms Takeaways: Invasive plants can be turned into sustainable meals. Garlic mustard is edible at every stage of growth. Kudzu grows rapidly and is edible in various forms. Japanese knotweed can be used in desserts and jams. Burdock root is rich in fiber and antioxidants. Proper identification is crucial when foraging. Invasive species can have significant ecological impacts. Foraging can help control invasive plant populations. Cooking with invasive plants can be delicious and eco-friendly. Community resources and local foraging groups are invaluable. Burdock requires effort to harvest but is versatile in cooking. Dandelions are nutritious and can be used in various dishes. Young dandelion leaves are best for salads, while mature ones are great sautéed. Dandelion jam is a delightful treat reminiscent of sunshine. Himalayan blackberries are delicious but invasive, dominating the West Coast. Eating invasive species is a form of stewardship for the land. Culinary conservation encourages conscious eating and seasonal food sourcing. Chapters: 00:00 Introduction to Invasive Edibles 01:20 The Impact of Invasive Plants 03:15 Garlic Mustard: The Ecological Villain 11:25 Kudzu: The Vine That Ate the South 18:00 Japanese Knotweed: A Destructive Invader 25:11 Burdock: The Versatile Root Vegetable 27:36 Exploring Burdock: A Culinary Gem 30:00 Dandelions: The Ubiquitous Superfood 39:41 Himalayan Blackberries: A Sweet Invasive Delight 45:01 Golden Oyster Mushrooms: A Culinary Invasion 50:02 Culinary Conservation: Eating for the Ecosystem Keywords: Invasive plants, edible plants, foraging, ecological eating, sustainable meals, garlic mustard, kudzu, Japanese knotweed, burdock, wild foods, burdock, dandelion, Himalayan blackberry, golden oyster mushroom, invasive species, culinary conservation, foraging, wild food, sustainability, nutrition Learn more about your ad choices. Visit megaphone.fm/adchoices

In 2023 an infestation of quagga mussels was found in the Snake River near Twin Falls.

Alyssa and Callum are joined by Dr Neil Stone to talk all things Rare, Invasive, and Mouldy. Specifically Fusarium spp., as well as Scedosporium spp. and Lomentospora prolificans. Heard of these before? No? Well listen in to find out what they are, and why they matterShow notes for this episode here: https://idiots.notion.site/122-Moulds-Rare-invasive-moulds-af70fc26e81043669c2bf3ef17c14b6c?pvs=74Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on Bluesky @idiots-pod.bsky.socialPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod

In this episode of the Nine Finger Chronicles podcast, host Dan speaks with Josh Rigg about hunting experiences, safety lessons learned from a hunting accident, and the dynamics of hunting regulations in Ohio. They discuss the importance of safety in hunting, the challenges of public versus private land hunting, and the ethical considerations surrounding hunting practices. The conversation also touches on wildlife management issues, including the impact of invasive species and the role of government regulations in hunting. Takeaways: Dayton, Ohio offers great outdoor activities like hunting and kayaking. Hunting safety is paramount; always keep your safety on. Hunting can lead to unexpected accidents; be prepared. Crossbows are legal in Ohio, but opinions on their use vary. Public land hunting can be crowded, especially during gun season. Ethical hunting practices are essential for conservation. Regulations can sometimes favor out-of-state hunters over residents. Wildlife management is a complex issue that requires community involvement. Invasive species like hogs pose significant challenges to local ecosystems. Engaging with local DNR meetings can influence hunting regulations. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Nine Finger Chronicles podcast, host Dan speaks with Josh Rigg about hunting experiences, safety lessons learned from a hunting accident, and the dynamics of hunting regulations in Ohio. They discuss the importance of safety in hunting, the challenges of public versus private land hunting, and the ethical considerations surrounding hunting practices. The conversation also touches on wildlife management issues, including the impact of invasive species and the role of government regulations in hunting. Takeaways: Dayton, Ohio offers great outdoor activities like hunting and kayaking. Hunting safety is paramount; always keep your safety on. Hunting can lead to unexpected accidents; be prepared. Crossbows are legal in Ohio, but opinions on their use vary. Public land hunting can be crowded, especially during gun season. Ethical hunting practices are essential for conservation. Regulations can sometimes favor out-of-state hunters over residents. Wildlife management is a complex issue that requires community involvement. Invasive species like hogs pose significant challenges to local ecosystems. Engaging with local DNR meetings can influence hunting regulations. Learn more about your ad choices. Visit megaphone.fm/adchoices

Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.Click here to read the full articleContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Anticipation is growing in both Israel and Gaza - as an exchange of the remaining Israeli hostages and Palestinians held in Israeli prisons is set to begin Monday morning. Meanwhile, world leaders are on their way the Egypt for an international peace summit.Also: Ottawa is expected to announce its second list of major nation-building infrastructure projects before the Grey Cup in Winnipeg next month. One of the potential projects is the 3-billion-dollar Kivalliq Hydro Fiber link. It would start in Manitoba - and connect western Nunavut to electric grids and high-speed internet. And: For the first time since 2016, the American League Championship Series is being played on this side of the border. The Toronto Blue Jays are hosting the Seattle Mariners tonight for Game 1. And there's a lot on the line for both teams. We'll take you to the field at Rogers Centre in Toronto.Plus: Taiwan caught in U.S.-China trade war, Global death report reveals some alarming new trends, Invasive weeds hurting Canadian farms, and more.

Welcome to another Retrospective episode, this time about wildflowers. This was originally recorded in 2019 as part of the radio show, Digging in with Master Gardeners on 90.7 WGXC FM. The content is still very relevant today, so we've repurposed it for our podcast format. In this episode, Tim and Jean sit down with Tracey Testo-Smith, Agroforestry and Natural Resources Program Manager at Cornell Cooperative Extension (CCE) of Columbia and Greene Counties. Tracey considers the Agroforestry Resource Center in the Siuslaw Teaching and Model Forest as her “specialty.” She leads frequent forest walks, and Part I of this interview is a chat about the wildflowers she observes. She explains the Siuslaw Forest's evolution from a logging resource to one of four model forests in the New York City/Catskill Watershed area. The forest is an education source and is frequently open to the public. So, when you want to learn about wildflowers and attend one of Tracey's walks, what should you expect? Tracey says to keep in mind three main features of most : wildflowers are; petal number and symmetry (odd or even number); leaf arrangement, whether opposite, alternate or whorled; the edges of the leaf, whether the margins are entire, toothed or lobed. With these three basic observations, you can begin to “key out” an iID for the plant you're looking at. Newcombe's Wildflower Guide is Tracey's favorite reference book. On her walks, Tracey likes to point out the more subtle flowers, while still admiring the showier “stars”, of course. There is also a grey area about non-native introduced flowers that have coexisted peacefully with the natives for, in some cases, centuries. These are acknowledged for their beauty and usefulness, too. In the Spring wildflower walks, the Ephemerals show off. These are plants with a specific lifestyle habit of appearing early in the year, growing to full maturity and producing seeds before disappearing, plant and all, until the next year. Tracey points out that sometimes plants are misnamed as ephemeral but arent because the foliage perseveres into the summer. One example of this is the Hepatica. A field trip, whether into the Siuslaw Forest or, often, the Hudson CCE campus, consists of the group gathering and reviewing how to use field guides before venturing outside to explore. Phone apps are discussed as well. Tracey admits a partiality to the Springtime. She points out that at that time of year, we're hungry for color and fresh plant life as the forest reawakens. When Tim asked about the rarest plant she'd observed, she described the green fringed orchid, a very subtle beauty that seems to “move around” from year to year. It's listed by the state as not “rare”, but “vulnerable.”Some plants are hunted, specifically ginseng. Once almost eradicated because of its value to herbalists and over-harvesting by landowners and poachers alike, wild stands of the plant are often kept secret by those who find them. Ginseng planbts typcally don't thrive when transplanted, so Tracey warns against thinking you can bring them home to grow them in “safety”. In fact, she advises against digging up any wild plant... it's usually a death sentence because its growing requirements are very specific. Other threats beside loving them to death (moving them) include climate change and invasive plants. Climate change interferes with the interrelations between plants, birds and animals that had evolved over millennia, when outside temperatures are no longer predictable by seasons. With extremes occurring more often, it stresses plant life. Invasive plants outcompete native plants for resources by sprouting earlier and lasting later into the seasons. The other major threat to wildflowers is deer browse. Tracey describes experimental “exclosures” build within the forest and observed over a number of years for effect on the plant population. There is an opportunity for citizen scientist volunteers to participate in the AVID program (see website link in the resources). Another way to participate is via the iMap invasive app, reporting on discovery and reporting of invasive plants. Hosts: Tim Kennelty and Jean Thomas Guest: Tracey Tesot-Smith Photo by: Teresa Golden Production assistance: Linda Aydlett, Deven Connelly, Teresa Golden, Tim Kennelty, Amy Meadow, Xandra Powers. Annie Scibienski, Jean Thomas Resources

Al & Jerry: When you simply hear a story about an invasive penis procedure, why do you feel that in your body? To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Al & Jerry: When you simply hear a story about an invasive penis procedure, why do you feel that in your body?--plus warm up To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

From 'Al & Jerry's Postgame Podcast' (subscribe here): When you simply hear a story about an invasive penis procedure, why do you feel that in your body? To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Join the October Menopause Challenge: https://drgabriellelyon.com/forever-strong-menopause-challenge/Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comWhen you hear the word “radiation,” do you think of cancer, Chernobyl, or an airport scanner? In this powerful episode, Dr. Gabrielle Lyon sits down with Dr. Sanjay Mehta, a radiation oncologist, to completely redefine your understanding of radiation as a tool for medicine.Dr. Mehta reveals how modern technology has made radiation oncology incredibly precise, minimizing side effects for cancer patients. He also shares groundbreaking insights into the underutilized field of low-dose radiation therapy, a safe and effective treatment for common inflammatory conditions like arthritis, tendinitis, and plantar fasciitis. This conversation is a must-watch for anyone with chronic pain or a fear of radiation, offering a new path to health and healing.Chapter Markers0:00 - Intro0:42 - The biggest myths about radiation1:33 - Dr. Sanjay Mheta's introduction2:07 - Radiation as a treatment for prostate cancer3:41 - The side effects of surgery vs. radiation4:32 - The training of a radiation oncologist5:34 - Full-body scans and diagnosis7:48 - What is radiation?9:00 - The difference between medicine and poison10:50 - The electromagnetic spectrum12:21 - Ionizing vs. Non-ionizing radiation13:42 - How we are naturally exposed to radiation15:50 - The biggest myth about radiation18:50 - Hormesis and low-dose radiation21:10 - The evolution of radiation technology22:38 - Radiation in daily life (dentist X-rays)25:00 - Can all cancers be destroyed by radiation?26:43 - Why radiation doesn't always burn skin28:25 - How radiation treatment is planned32:27 - Side effects of prostate cancer surgery33:09 - Penile shortening and prostate surgery36:00 - The role of testosterone in prostate cancer38:37 - How radiation affects bodybuilders39:09 - Who is not a candidate for radiation?41:33 - Is radiation the standard of care for all cancers?42:32 - Debunking radiation fear (microwaves, etc.)44:38 - The airport scanner debate47:03 - Other sources of radiation exposure52:32 - Grounding and radiation54:40 - Low-dose radiation for musculoskeletal injuries55:50 - The history of low-dose radiation57:22 - The use of radiation in the 1800s59:42 - Cortisone vs. low-dose radiation for pain1:03:00 - Dr. Ma's personal story of treatment1:04:07 - The duration and protocol of low-dose radiation1:08:16 - Inflammation and low-dose radiation1:10:59 - The durability of radiation therapy1:12:00 - Reversal of disease1:17:22 - Radiation's effect on hip pain1:18:29 - Treating rheumatoid arthritis1:20:29 - Post-operative radiation1:22:11 - Low-dose radiation for Peyronie's disease1:24:42 - What's holding back adoption of this therapy in the US?1:26:45 - The future of low-dose radiation1:27:31 - How to book an appointment with Dr. Mehta1:28:09 - Closing RemarksWho is Dr. Sanjay Mehta? Dr. Sanjay Mehta has been treating cancer patients for over 25 years using state of the art radiation oncology technology. He is now successfully treating patients with arthritis, tendonitis, and plantar fasciitis with low dose radiation using proven European regimens. It is non invasive, painless, and covered by Medicare and most insurance plans.This episode is brought to you by:PaleoValley - Get 15% off automatically at

Summary: This episode delves into the world of invasive birds, exploring their ecological impact and culinary potential. Justin and Adam discuss various species, including rock doves, Eurasian collared doves, songbirds, and waterfowl like snow geese and mute swans. They share insights on cooking techniques, flavor profiles, and sustainable practices for harvesting these birds. The conversation emphasizes the importance of viewing invasive species as a resource and encourages listeners to experiment with historical recipes and modern cooking methods. - ⁠⁠⁠Leave a Review of the Podcast⁠⁠⁠ - ⁠⁠⁠Buy our Wild Fish and Game Spices⁠⁠⁠ ⁠⁠⁠The Art of Venison Sausage Making⁠⁠⁠ Recipes: Breaking Up with Dove Poppers: Why It's Time to Move On Buttermilk Fried Dove & Waffles with Spicy Bourbon Maple Syrup Retro Recipe: Sous Vide Peking Dove with Pickled Veggies Sweet and Spicy Jalapeño Quail or Doves Roasted Doves and Maitake with Poblano Cream Sauce on Grits Tandoori Dove with Cilantro-Yogurt Sauce Takeaways: Invasive species can be a resource if harvested responsibly. Rock doves and Eurasian collared doves are common invasive birds in North America. Both doves are edible and can be prepared in various ways. Cooking techniques vary based on the age and type of bird. Songbirds like house sparrows and starlings are often overlooked as food sources. Mute swans are invasive and can be managed through hunting. Snow geese are abundant and provide high-quality meat. Cooking methods for waterfowl include roasting, braising, and grinding for sausage. Upland birds like pheasants are often introduced and considered game birds. Historical recipes can provide inspiration for cooking invasive species. Chapters: 00:00 Introduction to Invasive Species and Their Culinary Potential 02:53 Doves: The Rock Dove and Eurasian Collared Dove 05:55 Flavor Profiles and Cooking Techniques for Doves 08:44 Exploring Other Invasive Birds: Songbirds and Their Edibility 11:25 Harvesting and Cooking Techniques for Songbirds 14:36 Creative Recipes for Dove and Songbird Dishes 17:27 Culinary Traditions and Historical Context of Eating Invasive Birds 32:05 Exploring Urban Wildlife: Pigeons and Sparrows 34:03 The Invasive Mute Swan: A Threat to Native Species 34:29 Snow Geese: Conservation and Culinary Delights 38:20 Canada Geese: The Resident vs. Migratory Debate 41:31 Flavor Profiles of Waterfowl: Snow Geese vs. Canada Geese 46:07 Cooking Techniques for Waterfowl: From Plucking to Braising 51:17 Upland Birds: A Culinary Perspective 53:49 Peacocks: The Ornamental Bird with Culinary Potential 57:39 Final Thoughts on Invasive Birds and Cooking Techniques Keywords: Invasive species, hunting, cooking, doves, pigeons, songbirds, waterfowl, recipes, ecological impact, sustainable eating Learn more about your ad choices. Visit megaphone.fm/adchoices

On this week's Regional Roundup, a report on a crew of dogs helping to sniff out invasive weeds in Wyoming and a special quilting project honoring veterans in Western Colorado. PBS NewsHour science correspondent Miles O'Brien discusses the importance of science, and best-selling author Kevin Barry talks about the history of Irish miners migrating to the Rocky Mountain West in the late 1800s, the setting for his latest novel, The Heart in Winter.

This content was funded by AstraZeneca, and is intended for US Healthcare Professionals.   How do urologists, oncologists, and advanced practice providers coordinate care in muscle-invasive bladder cancer (MIBC)?   This AMJ podcast brings together three leading experts in each speciality to explore best practices in MDT collaboration, patient transitions, and treatment strategy.    Listen now to strengthen your approach to MIBC care.    Chapters: 00:00 – 02:18 | Introductions 02:18 – 10:15 | MDT Collaboration & Best Practices 10:15 – 16:16 | Patient Pathway & Coordination 16:16 – 25:23 | Treatment Decisions & Strategy 25:23 – 33:38 | Immune-Mediated AR Management 33:38 – 38:52 | Key Takeaways    Speakers:   Chandler Park, MD – Medical Oncologist, Norton Cancer Institute; & Clinical Faculty, University of Louisville School of Medicine   Gautam Jayram, MD – Urologist, Urology Associates, Nashville, TN   Michael White, PA-C – Physician Assistant, Urology Partners of North Texas

Trout fishing season has just kicked off and for anglers in Waikato, there are warnings to watch out for the super-spreading invasive golden clam. 

Eine invasive Ameisenart erobert Deutschland: die Große Drüsenameise, Tapinoma magnum. Diese Ameise gründet sogenannte Superkolonien, weitverzweigte Netzwerke von Nestern, die aus Hunderttausenden bis Millionen von Arbeiterinnen und Tausenden von fortpflanzungsfähigen Königinnen bestehen. Ganze Ökosysteme sind gefährdet. Stefan Troendle im Gespräch mit Axel Wagner, Autor der SWR-Dokumentation „Invasion der Ameise - Die unterschätzte Gefahr?“

Returning to the subject of invasive alien species, it is hard to imagine that some of these species might still be found for sale in some local garden centres around Ireland, but they are according to Noeleen Smyth, Assistant Professor in Environmental and Sustainable Horticulture at UCD.

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue.Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based chemotherapy. SunRISe-4 is a randomised, open-label, phase 2 trial being conducted at 109 investigative centres in ten countries worldwide, and aims to evaluate the safety and efficacy of neoadjuvant TAR-200 plus cetrelimab (anti-PD-1) versus cetrelimab monotherapy in this disease setting.They discuss the unique features of the TAR-200 localised sustained delivery system for gemcitabine, the key findings from the SunRISe4-trial trial, and what the future implications of the findings are in terms of better treatment options for patients with bladder cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00358-4/abstract?dgcid=buzzsprout_icw_podcast_September_25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

WXPR News for 9-25-25

This week we are not featuring a guest, but will be discussing Haemophilus influenzae, or H. influenzae, a kind of bacteria. It can cause bacterial infections ranging from mild (such as bronchitis) to severe (such as septic arthritis). Treatment includes antibiotics but you may also require hospitalization depending on the severity of your condition. Haemophilus influenzae (H. influenzae) is a type of bacteria that can cause several different kinds of infections. These bacterial infections can range from mild, such as ear infections, to severe, such as bloodstream infections. The infections typically affect children younger than 5 years old. They also affect people who are immunocompromised, such as those with certain medical conditions. Some H. influenzae infections are "invasive," which means the bacteria invade parts of your body that are normally free from germs. For instance, H. influenzae can invade the fluid surrounding your spinal cord and brain, which can cause meningitis. Meningitis is the swelling of the lining of your brain and spinal cord. Invasive diseases usually require hospital treatment and can sometimes be fatal. (Credits: Cleveland Clinic)

This week we are not featuring a guest, but will be discussing Haemophilus influenzae, or H. influenzae, a kind of bacteria. It can cause bacterial infections ranging from mild (such as bronchitis) to severe (such as septic arthritis). Treatment includes antibiotics but you may also require hospitalization depending on the severity of your condition. Haemophilus influenzae (H. influenzae) is a type of bacteria that can cause several different kinds of infections. These bacterial infections can range from mild, such as ear infections, to severe, such as bloodstream infections. The infections typically affect children younger than 5 years old. They also affect people who are immunocompromised, such as those with certain medical conditions. Some H. influenzae infections are “invasive,” which means the bacteria invade parts of your body that are normally free from germs. For instance, H. influenzae can invade the fluid surrounding your spinal cord and brain, which can cause meningitis. Meningitis is the swelling of the lining of your brain and spinal cord. Invasive diseases usually require hospital treatment and can sometimes be fatal. (Credits: Cleveland Clinic)  

BioPlaster from Mexico transforms invasive sargassum algae into high-performance, certified biodegradable materials that replace petroleum-based plastics in packaging and textiles. Their product line includes compostable films, bags, foams, and threads designed for circularity, industrial scalability, and environmental impact. Listen to the story of Andrea and Daniel, Co-founders of BioPlaster Research, about how they're taking the 38M metric tons of sargassum algae that washes up on the Caribbean coast every year and converting it into biodegradable solutions for the $900B plastic industry. They have over $5.3M in LOIs from partners like IKEA suppliers, Great Packaging, AbaMex, and our portfolio company Refurbi and will start commercialisation early 2026. Angel investors Lorena Compean and Stephanie Groen join the Investor Talk at the end of this podcast.Hosted by Maaike Doyer, founder of Epic Angels.

It all started harmlessly enough: People bought kits to grow mushrooms at home. But then, scientists in the upper Midwest noticed something strange. The golden oyster mushroom, which is not native to the United States, was thriving in local forests. Those homegrown mushrooms escaped our basements into the wild. Fungal ecologist Aishwarya Veerabahu joins Host Ira Flatow to discuss what impact these invasive mushrooms might have on the ecosystem.Plus, nightshade expert Sandra Knapp describes the evolution of the potato plant, and how a lucky crossbreeding millions of years ago may have given rise to the starchy tubers we eat today.Guests:Aishwarya Veerabahu is a fungal ecologist and PhD candidate at the University of Wisconsin-Madison.Dr. Sandra Knapp is a Merit Researcher at the Natural History Museum in London.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

On Wednesday, the Oregon Department of Forestry announced that the emerald ash borer has now been found in the Hazelwood neighborhood in East Portland and five other new sites in the north Willamette Valley. In addition to Portland, the highly invasive and destructive beetle has now been found near other urban areas in the region, including Beaverton, Banks and Oregon City. The Oregon Department of Agriculture said that the discovery of EAB in Portland has now put all of Multnomah County into the EAB quarantine zone, which also includes Washington, Yamhill, Marion and Clackamas counties.     Native to Asia, EAB was first detected in Oregon in 2022 at an elementary school in Forest Grove. Considered to be the most destructive forest pest in North America, EAB has killed over 100 million ash trees nationwide since its arrival in the U.S. more than 20 years ago.  Joining us to discuss the spread of EAB and how the public can help efforts to contain it are Cody Holthouse, manager of ODA’s  Insect Pest Prevention and Management Program and City of Portland Forester Jenn Cairo.

Interview with David C. Whiteman, MBBS, PhD, author of A Risk Prediction Tool for Invasive Melanoma. Hosted by Adewole S. Adamson, MD. Related Content: A Risk Prediction Tool for Invasive Melanoma

Interview with David C. Whiteman, MBBS, PhD, author of A Risk Prediction Tool for Invasive Melanoma. Hosted by Adewole S. Adamson, MD. Related Content: A Risk Prediction Tool for Invasive Melanoma

Alan interviews Tushar Sharma. Tushar Sharma grew up in a small village in India - but he had big plans. He graduated from IIT in Madras with a biotechnology degree. He completed his masters and PhD at UT Austin in Biomedical Engineering. In 2019, he invented a non-invasive surgical procedure for prostate patients that has minimal side effects. Website: www.VivifiMedical.com

Today... Montrose County Commissioner Scott Mijares will face a November recall election after declining to resign or challenge petitions, with supporters citing his conservative record and opponents accusing him of reckless, divisive leadership. And later... All Colorado water users—motorized or not—must clean, drain, and dry their gear to stop invasive zebra mussels from spreading and damaging ecosystems, recreation, and infrastructure.Support the show: https://www.montrosepress.com/site/forms/subscription_services/See omnystudio.com/listener for privacy information.

AP's Lisa Dwyer reports that an invasive species of tick is now in Maine.

Callum and Jame are joined by Iain and Darius to talk through the clinical aspects of managing Aspergillosis with a particular focus on the most severe disease. Listen in to hear about current challenges around the management of both invasive and chronic Aspergillosus.Notes for this episode here: https://idiots.notion.site/118-Moulds-Aspergillus-ce3ba58d045b47b18d9641b56559c6f5?pvs=74Send us a text Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on Bluesky @idiots-pod.bsky.socialPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod

Can crops change the weather? We've done the myth busting, learn the truth. Plus, PRCA standings heat up - we talk Rodeo, share how a rancher raises Old Glory sky-high, and fishing records are about to be broken again! Join radio hosts Rebecca Wanner aka ‘BEC' and Jeff ‘Tigger' Erhardt (Tigger & BEC) with the latest in Outdoors & Western Lifestyle News! Season 5, Episode 253 Can Crops Affect the Weather? Chief Meteorologist Kenny Miller Explains When it comes to agriculture, we usually think about how weather affects crops — but what if the reverse is true? Can crops actually influence the weather? According to KX News Chief Meteorologist Kenny Miller, who has extensive experience in forecasting for agriculture and commodity trading, the answer is yes — in certain ways. “Large-scale crops can change local climate conditions through evapotranspiration,” says Miller. “That's the process where plants release moisture back into the atmosphere, which can lead to cooler temperatures and increased local humidity.” This matters not only for farmers, but also for agriculture professionals and commodity traders who rely on precise, short-term forecasts during critical planting and harvest windows. Kenny emphasizes that the impact is regional, not global — but in key ag zones, it can shape everything from yield timing to market behavior. PRCA Standings: Countdown to the 2025 Wrangler NFR As we approach the PRCA regular season deadline on September 30, 2025, the tension is building across the rodeo world. Cowboys and cowgirls across the country are laser-focused on making the Top 15 in their events to qualify for the Wrangler National Finals Rodeo (NFR) this December. Current PRCA Standings Here are the PRCA Rankings & Standings as of September 2, 2025. Stetson Wright, Beaver, Utah: All-Around Earnings: $391,000 plus. After the 8x World Champion sustained injuries at the 2023 NFR, sidelined during the 2024 rodeo season, he has made a runaway comeback for the coveted 2025 Wrangler NFR All-Around Champion. Events: #1 in Bull Riding, #9 in Saddle Bronc. Rocker Steiner, Weatherford, TX: World bareback riding leader with $243,000 plus with the closest contender being Bradlee Miller of Huntsville, TX and Jess Pope of Waverly, KS riding neck in neck with just a $1,000 year earnings in difference fighting for that 2nd place title. Ryder Wright, Beaver Utah: Saddle Bronc Earnings: $273,000 plus. Saddle Bronc this year is a tighter event. The top 12 in the world fighting for their seat in the winners circle have all earned well over $150,000… This includes well known names such as Damian Brennen in 2nd with Dawson Hay right behind, Brody Wells, and Zeke Thurston all over $200,000 in 2025 earnings. Following not far behind are Ryder Wright's brothers…  Statler Wright sitting in 6th, and Stetson Wright in 9th. And a shoutout to a friend of the show, Melstone, Montana cowboy Sage Newman, is right up there too sitting in 6th. Will Lummus, Byhalia, Missouri: Steer Wrestling leader with $161,000 in earnings. Tanner Tomlinson, Mineral Wells, Texas is the current world leader Team Roping Header with $153,000 plus, however it's a TIGHT race as a household favorite here Derrick Begay of Arizona is just $3,000 behind in earnings. Remember last year during the 2024 Wrangler NFR when Derrick Begay borrowed his well-known mule, John Henry, to saddle bronc favorite Zeke Thurston to ride in the first two Grand Entry parades! Levi Lord, Sturgis, South Dakota is the current world leader Team Roping Heeler with $155,000 plus. This 4x NFR qualifier is making sure the world knows there's more to Sturgis, South Dakota than just a HUGE motorcycle rally. Riley Webb, Denton, Texas is the current world leader Tie-Down Roping with $264,000 in earnings. Not a bad place to be after 2024 being his WNFR debut. Chasing him is 6x qualifier Shad Mayfield sitting with over $237,000. Cole Patterson, Pawnee, OK is currently leading world standings in Steer Roping with over $92,000. Kassie Mowry, Dublin, Texas is the world barrel racing leader at $202,000 plus in earnings. The top three looking to make this a race to watch just like in 2024 also include Texas stars Brittany Pozzi Tonozzi and Hailey Kinsel. But don't leave out the legend Lisa Lockhart as she's sitting 10th and this cowgirl knows the grind, and how to move mountains. That's just a quick snapshot of current standings as we look forward towards the Wrangler National Finals Rodeo (NFR) this December. Dates for Wrangler Finals National Rodeo: December 4 - December 13, 2025 Location: Thomas & Mack Center in Las Vegas, Nevada Reference: https://www.prorodeo.com/standings?eventType=AA&standingType=world&id=&circuitId=&year=2025 Outdoors & Western Lifestyle News 78-Year-Old Rancher Climbs 130-Foot Flagpole to Keep Old Glory Flying High When a storm took down the ropes on a 130-foot flagpole in Star Valley, Wyoming — most folks would've called it a job for the young and fearless. But not Darcel Hulse. At 78 years old, the rancher grabbed his gear, called a crane, and went straight up to fix it himself. That's because flying the American flag isn't just tradition on his Salt River Ranch — it's a statement. Hulse proudly flies a 1,500-square-foot flag from the highest point on his property, and when it needed replacing, he wasn't about to sit it out. Recently in a Cowboy State Daily interview, Darcel Hulce joked, 'I'm an old guy, but I'm not afraid of heights.” And judging by the 1.4 million views on his daughter's video of the flag-raising, the country loves him for it. The massive flag — 50 by 30 feet — has become a beloved landmark in Star Valley. Locals call it “our flag,” and when it was temporarily down, the phones lit up. Everyone wanted to know when Old Glory would be back. For Hulse, raising that flag is about more than patriotism. It's about values, family, and returning to his Western roots. And while he hopes that new rope holds strong for a while — you can bet that if it doesn't, he'll be right back up there making sure that star-spangled banner keeps waving high. Reference: https://cowboystatedaily.com/2025/08/31/78-year-old-rancher-scales-130-foot-flagpole-to-fly-massive-american-flag-over-star-valley/  Alaska Bans Invasive Berry Trees to Protect Native Forests and Wildlife A major move from Alaska officials this week — the state has officially banned two popular but destructive trees: the mayday tree and the chokecherry. These fast-growing ornamentals were once a garden favorite, but they've turned into a serious threat to Alaska's natural landscape. The ban — now statewide — blocks the import, transport, or sale of these trees, which have overrun native birch and spruce forests, especially around Anchorage and Fairbanks. They may look pretty, but they're wreaking havoc under the surface. Their berries? Toxic to moose. Their roots? So tough, new trees grow right out of the stumps. And now, they're even spreading a nasty fungal disease known as Black Knot. Not exactly the kind of greenery you want in your backyard. The good news? Officials are working hard to remove them and replace them with native trees, and this new ban is a big step forward. As Division of Agriculture Director Bryan Scoresby puts it: ‘With this quarantine, the flow of trees into Alaska will stop, making the goal of elimination more attainable.' So next time you're planting something new, remember — going native helps keep eco-systems wild, balanced, and beautiful. Check your state on plants that have landed on the Noxious or Invasive list by reaching out to your local extension agent. Reference: https://alaskabeacon.com/briefs/alaska-officials-impose-statewide-ban-on-invasive-berry-producing-trees/ Swordfish That ‘Looked Like a Dinosaur' Could Shatter Alabama Record An Alabama fishing trip turned legendary when Robert Fritze and his crew caught a massive 550.3-pound swordfish—over 100 pounds heavier than the current state record. The catch happened in the early morning hours of August 15, after the crew set out from Orange Beach Marina aboard the Trade Desk. Originally aiming for marlin, the six-man crew fished near deep-water oil rigs, dropping a squid bait setup hundreds of feet down overnight. Around 4 a.m., Robert noticed the reel clicking and jumped into the fighting chair for what became a four-and-a-half-hour battle. The swordfish fought hard and deep before finally surfacing—stunning the crew with its dinosaur-like appearance. Once landed, the fish was so big it filled the entire deck, forcing the crew to end their trip early. The swordfish measured 150 inches long with a 62-inch girth and is expected to break Alabama's current record of 448 pounds, pending official approval. Now my question is - Where does one find the wall space to hang a mount that big?! Reference:  https://www.outdoorlife.com/fishing/alabama-possible-record-swordfish/ OUTDOORS FIELD REPORTS & COMMENTS We want to hear from you! If you have any questions, comments, or stories to share about bighorn sheep, outdoor adventures, or wildlife conservation, don't hesitate to reach out. Call or text us at 305-900-BEND (305-900-2363), or send an email to BendRadioShow@gmail.com. Stay connected by following us on social media at Facebook/Instagram @thebendshow or by subscribing to The Bend Show on YouTube. Visit our website at TheBendShow.com for more exciting content and updates! https://thebendshow.com/ https://www.facebook.com/thebendshow WESTERN LIFESTYLE & THE OUTDOORS Jeff ‘Tigger' Erhardt & Rebecca ‘BEC' Wanner are passionate news broadcasters who represent the working ranch world, rodeo, and the Western way of life. They are also staunch advocates for the outdoors and wildlife conservation. As outdoorsmen themselves, Tigger and BEC provide valuable insight and education to hunters, adventurers, ranchers, and anyone interested in agriculture and conservation. With a shared love for the outdoors, Tigger & BEC are committed to bringing high-quality beef and wild game from the field to your table. They understand the importance of sharing meals with family, cooking the fruits of your labor, and making memories in the great outdoors. Through their work, they aim to educate and inspire those who appreciate God's Country and life on the land. United by a common mission, Tigger & BEC offer a glimpse into the life beyond the beaten path and down dirt roads. They're here to share knowledge, answer your questions, and join you in your own success story. Adventure awaits around the bend. With The Outdoors, the Western Heritage, Rural America, and Wildlife Conservation at the forefront, Tigger and BEC live this lifestyle every day. To learn more about Tigger & BEC's journey and their passion for the outdoors, visit TiggerandBEC.com. https://tiggerandbec.com/

Tendon pain can limit mobility and linger for months. Sometimes rest and rehab aren't enough. A new generation of a minimally invasive device in the hands of doctors at The University of Kansas Health System is now helping patients avoid surgery and get the relief they need.

Drs. Petri and Fava review non-invasive biomarkers in systemic lupus erythematosus, including urine proteomics.

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

An invasive plant newly identified in Wisconsin called Japanese Stiltgrass. A preview of this year's Milwaukee Short Film Festival, which is showing 75 films in three days. A love letter to local paleteros.

This episode of 'Maximize Your Hunt' features a discussion on the importance of wetlands in hunting properties, focusing on their role in deer habitat and waterfowl management. Jon Teater (Whitetail Landscapes) and Eric Lance (Hunt Science) focus their conversation on food plot management, soil remediation, and the significance of plant selection for maintaining water quality and biodiversity. The speakers emphasize the need for careful planning and management of wetland areas, including the challenges posed by invasive species and the benefits of controlled burning. The episode concludes with encouragement for listeners to engage with local conservation agencies to enhance their wetland areas. Takeaways: Wetlands provide essential habitat for both deer and waterfowl. Food plots should be managed with attention to soil health and plant diversity. Emergent species in wetlands can serve as forage for deer. Water quality is critical for the health of wetland ecosystems. Invasive species management is a key aspect of wetland maintenance. Controlled burning can help reset plant communities and promote growth. Hunting pressure can negatively impact wildlife populations. Engaging with local conservation agencies can provide valuable resources. Diversity in plant life enhances habitat quality for wildlife. Wetland restoration is a worthwhile investment for landowners.   Social Links https://whitetaillandscapes.com/ https://www.facebook.com/whitetaillandscapes/ https://www.instagram.com/whitetail_landscapes/?hl=en https://podcasts.apple.com/us/podcast/the-huntscience-podcast/id1646115040 https://www.instagram.com/huntscience_podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode of 'Maximize Your Hunt' features a discussion on the importance of wetlands in hunting properties, focusing on their role in deer habitat and waterfowl management. Jon Teater (Whitetail Landscapes) and Eric Lance (Hunt Science) focus their conversation on food plot management, soil remediation, and the significance of plant selection for maintaining water quality and biodiversity. The speakers emphasize the need for careful planning and management of wetland areas, including the challenges posed by invasive species and the benefits of controlled burning. The episode concludes with encouragement for listeners to engage with local conservation agencies to enhance their wetland areas.Takeaways:Wetlands provide essential habitat for both deer and waterfowl.Food plots should be managed with attention to soil health and plant diversity.Emergent species in wetlands can serve as forage for deer.Water quality is critical for the health of wetland ecosystems.Invasive species management is a key aspect of wetland maintenance.Controlled burning can help reset plant communities and promote growth.Hunting pressure can negatively impact wildlife populations.Engaging with local conservation agencies can provide valuable resources.Diversity in plant life enhances habitat quality for wildlife.Wetland restoration is a worthwhile investment for landowners. Social Linkshttps://whitetaillandscapes.com/https://www.facebook.com/whitetaillandscapes/https://www.instagram.com/whitetail_landscapes/?hl=enhttps://podcasts.apple.com/us/podcast/the-huntscience-podcast/id1646115040https://www.instagram.com/huntscience_podcast/

Mrasek, Volker www.deutschlandfunk.de, Forschung aktuell

It's no secret that nationwide invasive aquatic plants are a problem, it's also no secret that people everywhere, generally speaking, don't like the fact that herbicides are used in the attempted mitigation of invasive aquatic plants. Especially in Florida. Now I'm not telling you were about to give you the answers, in fact you'll probably be left with more questions, titan when you started but you might also realize that you might have been asking the wrong questions this whole time. I know I did. UPO Gear & Such- https://uponation.co/ UPO Social Media- https://linktr.ee/underpressureoutdoorsHazmore Outdoor Products- https://hazmore.net/Use Code UPO15 at checkout for 15% off your next order!HangFree- https://hangfree.co/ Use code UPO10 at checkout for 10% off your next order!Water Feather Boats- https://waterfeathers.com/ Find a Dealer Near YouBecome a Patron- https://www.patreon.com/user?u=45295718

A key part of symptom management, agitation management, and humanizing care is communication. Throughout the podcast, we have discussed non-verbal communication during mechanical ventilation. ....but what about non-invasive ventilation? How does the inability to communicate impact care, patient experience, and outcomes for patient on BIPAP? Dr. Ian Wong shares with us his research and innovation that is transforming communication during non-invasive ventilation. Randomized Controlled Trial of a Novel Communication Device Assessed During Noninvasive Ventilation Therapy - PubMedAtaia Medical – Empowering Patients with the Freedom to Speakwww.DaytonICUConsulting.com

They’re on pavement, in gardens and in parks. If you’re in the Northeast, you’ve probably seen a spotted lanternfly this summer. The invasive species has spread to 19 states where they chow down on dozens of plants, especially grape vines. Deema Zein reports. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Seagulls are everywhere in the Bay Area — flocking to Giant's games in San Francisco and crowding South Bay salt ponds. But are they actually native? Once seasonal visitors from Mono Lake, they've recently become year-round residents. We get to the bottom of this gull invasion. Additional Resources: Are California Gulls Native or Invasive to the Bay Area? Maybe Both Read the transcript for this episode Sign up for our newsletter Enter our Sierra Nevada Brewing Company monthly trivia contest Got a question you want answered? Ask! Your support makes KQED podcasts possible. You can show your love by going to https://kqed.org/donate/podcasts This story was reported by Pauline Bartolone. Bay Curious is made by Katrina Schwartz, Gabriela Glueck and Christopher Beale. Additional support from Olivia Allen-Price, Jen Chien, Katie Sprenger, Maha Sanad, Alana Walker, Ethan Toven-Lindsey and everyone on Team KQED.